RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Guardant Health Stock

Guardant Health Revenue 2024

Guardant Health Revenue

716.26 M USD

Ticker

GH

ISIN

US40131M1099

WKN

A2N5RY

In 2024, Guardant Health's sales reached 716.26 M USD, a 27.01% difference from the 563.95 M USD sales recorded in the previous year.

The Guardant Health Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e2.1815,45
2028e1.4123,89
2027e1.227,96
2026e1.0232,93
2025e0.8539,76
2024e0.7247,04
20230.5659,74
20220.4565,38
20210.3767,27
20200.2967,74
20190.2167,02
20180.0952,32
20170.0536,55
20160.0312,30

Guardant Health Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Guardant Health, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Guardant Health from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Guardant Health’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Guardant Health. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Guardant Health’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Guardant Health’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Guardant Health’s growth potential.

Guardant Health Revenue, EBIT and net profit per share

DateGuardant Health RevenueGuardant Health EBITGuardant Health Net Income
2029e2.18 B undefined0 undefined286.37 M undefined
2028e1.41 B undefined-295.4 M undefined186.26 M undefined
2027e1.2 B undefined-305.11 M undefined-51.95 M undefined
2026e1.02 B undefined-318.8 M undefined-270.52 M undefined
2025e847.3 M undefined-370.26 M undefined-340.87 M undefined
2024e716.26 M undefined-394.31 M undefined-406.64 M undefined
2023563.95 M undefined-564.73 M undefined-479.45 M undefined
2022449.5 M undefined-544.4 M undefined-654.6 M undefined
2021373.7 M undefined-411 M undefined-405.7 M undefined
2020286.7 M undefined-255 M undefined-253.8 M undefined
2019214.4 M undefined-82.4 M undefined-75.7 M undefined
201890.6 M undefined-93 M undefined-85.1 M undefined
201749.8 M undefined-76.6 M undefined-89 M undefined
201625.2 M undefined-43.8 M undefined-46.1 M undefined

Guardant Health stock margins

The Guardant Health margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Guardant Health. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Guardant Health.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Guardant Health's sales revenue. A higher gross margin percentage indicates that the Guardant Health retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Guardant Health's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Guardant Health's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Guardant Health's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Guardant Health. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Guardant Health's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Guardant Health Margin History

Guardant Health Gross marginGuardant Health Profit marginGuardant Health EBIT marginGuardant Health Profit margin
2029e59.74 %0 %13.13 %
2028e59.74 %-20.95 %13.21 %
2027e59.74 %-25.32 %-4.31 %
2026e59.74 %-31.16 %-26.44 %
2025e59.74 %-43.7 %-40.23 %
2024e59.74 %-55.05 %-56.77 %
202359.74 %-100.14 %-85.02 %
202265.38 %-121.11 %-145.63 %
202167.27 %-109.98 %-108.56 %
202067.74 %-88.94 %-88.52 %
201967.02 %-38.43 %-35.31 %
201852.32 %-102.65 %-93.93 %
201736.55 %-153.82 %-178.71 %
201612.3 %-173.81 %-182.94 %

Guardant Health Aktienanalyse

What does Guardant Health do?

Guardant Health Inc is an American company specializing in the development of non-invasive diagnostic tests for cancer. The company was founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz. The two founders had previously successfully founded a company specialized in the development of blood tests for pregnancies. Guardant Health's goal is to detect traces of cancer cells in the blood of patients to enable early cancer diagnosis. Based on the liquid biopsy tests offered by the company, doctors can identify tumor cells and genetic mutations without relying on invasive methods such as tissue sampling. This allows for faster diagnosis and quicker treatment decision-making. Guardant Health's business model is based on the commercialization of its liquid biopsy tests, which are based on specially developed DNA sequencing methods. The company offers both diagnostic tests that can aid in cancer identification, as well as tests that can help doctors monitor the success of cancer therapies. Guardant Health has directed its offerings towards multiple products and divisions, including Guardant360, GuardantOmni, and GuardantReveal. Each of these products aims to solve specific challenges related to cancer diagnosis and treatment. Guardant360 is a diagnostic test specifically developed to help doctors sequence the DNA of cancer cells in the blood of patients and identify the genetic changes contributing to tumor growth. On the other hand, GuardantOmni is a liquid biopsy test that targets a broader range of cancer types. It enables a comprehensive genetic scan of cancer cells in the blood to identify specific mutations that can aid in tracking disease progression and selecting appropriate therapies. GuardantReveal is a test aimed at monitoring patients at higher risk of cancer. The test can be used to detect early signs of tumors in patients who are at higher risk due to their family history, age, or other factors. Guardant Health has achieved considerable success in the field of liquid biopsy detection in recent years. Currently, more than 100,000 patients worldwide have access to Guardant Health's liquid biopsy-based tests. The company is based in Redwood City, California, and employs over 1,000 employees. It has a broad investor base, including The SoftBank Vision Fund, Sequoia Capital, Lightspeed Venture Partners, and Khosla Ventures. Overall, the company has raised over $550 million in funding. Guardant Health aims to revolutionize the world of cancer diagnostics and treatment. By radically changing the process of diagnosing and monitoring cancer patients, the company aims to improve the survival rate of cancer patients and make cancer treatment more effective overall. Guardant Health ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Guardant Health's Sales Figures

The sales figures of Guardant Health originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Guardant Health’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Guardant Health's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Guardant Health’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Guardant Health stock

How much revenue did Guardant Health generate this year?

Guardant Health has achieved a revenue of 716.26 M USD this year.

How much was the turnover of the company Guardant Health compared to the previous year?

The revenue of Guardant Health has increased by 27.01% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Guardant Health?

The revenue of Guardant Health is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Guardant Health measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Guardant Health so important for investors?

The revenue of Guardant Health is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Guardant Health pay?

Over the past 12 months, Guardant Health paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Guardant Health is expected to pay a dividend of 0 USD.

What is the dividend yield of Guardant Health?

The current dividend yield of Guardant Health is .

When does Guardant Health pay dividends?

Guardant Health pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Guardant Health?

Guardant Health paid dividends every year for the past 0 years.

What is the dividend of Guardant Health?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Guardant Health located?

Guardant Health is assigned to the 'Health' sector.

Wann musste ich die Aktien von Guardant Health kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Guardant Health from 10/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/5/2024.

When did Guardant Health pay the last dividend?

The last dividend was paid out on 10/5/2024.

What was the dividend of Guardant Health in the year 2023?

In the year 2023, Guardant Health distributed 0 USD as dividends.

In which currency does Guardant Health pay out the dividend?

The dividends of Guardant Health are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Guardant Health

Our stock analysis for Guardant Health Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Guardant Health Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.